Medicine and Dentistry
Radiation Therapy
100%
Oropharynx Carcinoma
94%
Intensity Modulated Radiation Therapy
71%
Head and Neck Cancer
69%
Proton Therapy
59%
Neck
52%
Diseases
41%
Overall Survival
37%
Neoplasm
29%
Recurrent Disease
25%
Anaplastic Thyroid Carcinoma
23%
Malignant Neoplasm
21%
Plummer-Vinson Syndrome
21%
Wart Virus
20%
Magnetic Resonance Imaging
20%
Patient-Reported Outcome
19%
Re-Irradiation
16%
Cancer
16%
Squamous Cell Carcinoma
13%
Xerostomia
13%
Quality of Life
12%
Progression Free Survival
12%
Induction Chemotherapy
12%
Survival Rate
12%
Skull Base
11%
Carcinoma
11%
Head and Neck Squamous Cell Carcinoma
10%
Computer Assisted Tomography
10%
Oropharynx Squamous Cell Carcinoma
9%
Photon Therapy
9%
Tonsil Cancer
9%
Lymph Node
9%
Systemic Therapy
8%
Drug Megadose
8%
Chemoradiotherapy
8%
Tongue
8%
Bone Necrosis
8%
Hazard Ratio
8%
Clinical Trial
7%
Cranial Neuropathy
7%
Odds Ratio
7%
Radiation Oncology
7%
Nasopharynx Carcinoma
7%
Laryngeal Cancer
7%
Larynx
6%
Cohort Analysis
6%
Primary Tumor
6%
Cancer Therapy
6%
Metastatic Carcinoma
6%
Neck Dissection
5%
Keyphrases
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
58%
Head-and-neck Cancer
40%
Radiotherapy
29%
Radiation Therapy
28%
Anaplastic Thyroid Cancer
27%
Intensity-modulated Radiation Therapy
26%
Overall Survival
21%
Head-and-neck
21%
Intensity-modulated Proton Therapy
20%
Proton Therapy
17%
Cancer Patients
16%
Intensity-modulated Radiotherapy
16%
Nasopharyngeal Carcinoma
15%
Re-irradiation
13%
High-risk Human Papillomavirus (HR-HPV)
13%
Induction Chemotherapy
12%
Confidence Interval
11%
Progression-free Survival
10%
Tumor
10%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
9%
Cancer Survivors
8%
Patient-reported Outcomes
8%
MD Anderson Symptom Inventory (MDASI)
8%
Chemotherapy
7%
Locoregional Control
7%
Hazard Ratio
7%
Survival Outcomes
7%
Median Overall Survival
7%
Disease Control
7%
Local Control
7%
Intensity-modulated
7%
Failure Pattern
7%
Survivors
7%
Clinical Outcomes
7%
BRAF V600E
6%
Symptom Burden
6%
Phase II Trial
6%
Skull Base
6%
Odds Ratio
6%
Concurrent Chemotherapy
6%
Definitive Radiotherapy
6%
Locally Advanced
6%
Overall Survival Rate
6%
Recurrent Disease
5%
High Dose
5%
Dysphagia
5%
Quality of Life
5%
Neck Dissection
5%
Toxicity Outcomes
5%